Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Riddle

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Environmental Quality|June 5, 2018
Phosphorus Leaching from an Organic and a Mineral Arable Soil in a Rainfall Simulation StudyMatthew Riddle, Lars Bergström, Frank Schmieder, et al.
Journal of Diabetes and Its Complications|May 27, 2014
Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trialJulio Rosenstock, Vivian Fonseca, Stefan Schinzel, et al.
Diabetes Care|August 19, 2007
Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulinMatthew Riddle, Juan Frias, Bei Zhang, et al.
Diabetes/Metabolism Research and Reviews|September 27, 2014
Patterns of postprandial hyperglycemia after basal insulin therapy: individual and regional differencesCharles Shaefer, Timothy Reid, Andres DiGenio, et al.
Diabetes/Metabolism Research and Reviews|November 15, 2011
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysisAjay Chaudhuri, Julio Rosenstock, Andres DiGenio, et al.
Diabetes Care|June 13, 2015
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes, Jeffrey L Probstfield, Irl Hirsch, et al.
Diabetes, Obesity & Metabolism|August 7, 2024
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetesGrit Andersen, Rosy Eloy, Tim Heise, et al.
Diabetes, Obesity & Metabolism|January 12, 2023
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetesGrit Andersen, Rosy Eloy, Susanne Famulla, et al.
Diabetes Care|May 24, 2014
Insulin therapy in people with type 2 diabetes: opportunities and challenges?Philip Home, Matthew Riddle, William T Cefalu, et al.
Diabetes Care|October 25, 2014
Response to comment on Home et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes care 2014;37:1499-1508Philip Home, Matthew Riddle, William T Cefalu, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Environmental Quality|June 5, 2018
Phosphorus Leaching from an Organic and a Mineral Arable Soil in a Rainfall Simulation StudyMatthew Riddle, Lars Bergström, Frank Schmieder, et al.
Journal of Diabetes and Its Complications|May 27, 2014
Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trialJulio Rosenstock, Vivian Fonseca, Stefan Schinzel, et al.
Diabetes Care|August 19, 2007
Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulinMatthew Riddle, Juan Frias, Bei Zhang, et al.
Diabetes/Metabolism Research and Reviews|September 27, 2014
Patterns of postprandial hyperglycemia after basal insulin therapy: individual and regional differencesCharles Shaefer, Timothy Reid, Andres DiGenio, et al.
Diabetes/Metabolism Research and Reviews|November 15, 2011
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysisAjay Chaudhuri, Julio Rosenstock, Andres DiGenio, et al.
Diabetes Care|June 13, 2015
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes, Jeffrey L Probstfield, Irl Hirsch, et al.
Diabetes, Obesity & Metabolism|August 7, 2024
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetesGrit Andersen, Rosy Eloy, Tim Heise, et al.
Diabetes, Obesity & Metabolism|January 12, 2023
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetesGrit Andersen, Rosy Eloy, Susanne Famulla, et al.
Diabetes Care|May 24, 2014
Insulin therapy in people with type 2 diabetes: opportunities and challenges?Philip Home, Matthew Riddle, William T Cefalu, et al.
Diabetes Care|October 25, 2014
Response to comment on Home et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes care 2014;37:1499-1508Philip Home, Matthew Riddle, William T Cefalu, et al.
Pageof 3